Related Experiment Video
Updated: Jun 13, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Immunization as treatment for Parkinson's disease
Daniela Besong Agbo1, Frauke Neff, Florian Seitz
1Department of Neurology, Philipps-University Marburg, Marburg, Germany.
Journal of Neural Transmission. Supplementum
|April 24, 2010
Summary
Immunization strategies are being explored as a novel therapy for Parkinson's disease (PD). This review examines the current status of immune-based approaches for treating PD by targeting misfolded proteins.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Parkinson's disease (PD) and other neurodegenerative disorders involve the aggregation of misfolded proteins, disrupting neuronal networks.
- Cellular defense failures like autophagy and the ubiquitin-proteasome pathway contribute to disease progression.
- Current treatments for PD do not effectively halt or modify the disease's course.
Purpose of the Study:
- To review the current status of immune-based therapeutic approaches for Parkinson's disease.
- To explore the potential of immunization strategies in managing neurodegenerative proteinopathies.
Main Methods:
- Review of existing literature on immune-based therapies for neurodegenerative disorders.
- Focus on active and passive immunization strategies relevant to Parkinson's disease.
- Analysis of preclinical and clinical trial data for immune-based PD treatments.
Main Results:
- Immunization approaches have shown promise in animal models of neurodegenerative diseases.
- Clinical trials for Alzheimer's disease are already underway, suggesting broader applicability.
- The review synthesizes current research on immune-based strategies for PD.
Conclusions:
- Immune-based approaches, including active and passive immunization, represent a promising therapeutic avenue for Parkinson's disease.
- Further research and clinical trials are warranted to establish the efficacy and safety of these immunotherapies.
- Targeting misfolded protein aggregation through immune modulation offers a potential disease-modifying strategy for PD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:17Poliomyelitis
Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.